Biotech · Private company · Somerset, NJ, US

Targeted Therapy Technologies, LLC

Track this companyFree. Adds Targeted Therapy Technologies, LLC to your Dealase workspace and tells you when its record changes.

Clinical trials51 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline5

Chemoplaque also referred to as Episcleral TopotecanPhase 2 · RetinoblastomaClinicalTrials.gov · fetched Nov 12, 2026
Episcleral CelecoxibPhase 1 · Macula EdemaClinicalTrials.gov · fetched Nov 12, 2026
Episcleral DexamethasonePhase 1 · Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
Episcleral DexamethasonePhase 1 · Refractory Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
Episcleral TopotecanPhase 1 · RetinoblastomaClinicalTrials.gov · fetched Nov 12, 2026

Retinoblastoma Phase II Expanded Access Clinical TrialPHASE2 · RECRUITING · started Feb 21, 2025ClinicalTrials.gov NCT06679634 · fetched Nov 12, 2026
Topotecan Episcleral Plaque for Treatment of RetinoblastomaPHASE1 · UNKNOWN · started Jun 16, 2021ClinicalTrials.gov NCT04156347 · fetched Nov 12, 2026
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior PolePHASE1 · UNKNOWN · started Mar 5, 2021ClinicalTrials.gov NCT04120636 · fetched Nov 12, 2026
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior PolePHASE1 · UNKNOWN · started Sep 1, 2019ClinicalTrials.gov NCT04120311 · fetched Nov 12, 2026
A Phase I Study of Episcleral Dexamethasone for Treatment of Macular EdemaPHASE1 · UNKNOWN · started Apr 3, 2019ClinicalTrials.gov NCT04005430 · fetched Nov 12, 2026

Retinoblastoma Phase II Expanded Access Clinical TrialFiscal year 2026 · $650KNIH RePORTER 5R01FD008443-02 · fetched Nov 12, 2026
Retinoblastoma Phase II Expanded Access Clinical TrialFiscal year 2024 · $650KNIH RePORTER 1R01FD008443-01 · fetched Nov 12, 2026